CellMax Life
CellMax Life is a biotechnology company specializing in non-invasive blood tests for early cancer detection, including a pioneering test for colon cancer screening.
Services
CellMax Life develops non-invasive, accurate blood tests designed for the early detection of cancer. Their notable offering is the FirstSightTM blood test, which focuses on colon cancer screening and prevention. These advanced tests leverage patented technology to detect precancer and cancer cells in blood, aiming to provide an improved screening option compared to current non-invasive methods.
Products
The key product of CellMax Life is the FirstSightTM blood test, recognized as the first blood test primarily for colon cancer screening and prevention. This innovative test is built on their patented technology, which is optimized for detecting precancerous and cancerous cells in blood samples. One of the significant advantages of the FirstSightTM test is its potential to reduce colorectal cancer mortality by addressing early-stage adenomas that current non-invasive options often miss.
Headquarters
CellMax Life is headquartered in Sunnyvale, California. In addition to their primary location, they also maintain an office in New Taipei City, Taiwan. These locations enable CellMax Life to leverage diverse technological and medical expertise from both regions.
Technology
CellMax Life employs a patented technology designed to identify precancerous and cancerous cells in blood samples effectively. This technology is a cornerstone of their mission to improve cancer detection. By targeting adenomas, their technology aims to fill the gaps left by current non-invasive screening methods, which often fail to detect these early precancerous polyps.
Target Population
Around 125+ million Americans are recommended for routine screening according to national guidelines, all of whom could potentially benefit from CellMax Life's proprietary blood test. Their solutions are tailored to provide more accurate and less invasive screening options, catering to a significant portion of the population that requires consistent, reliable cancer detection methods.